We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Latanoprost Versus Fotil

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00304785
First Posted: March 20, 2006
Last Update Posted: October 24, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pharmaceutical Research Network
  Purpose
To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Condition Intervention Phase
Open-Angle Glaucoma Ocular Hypertension Drug: latanoprost 0.005% Drug: Fotil Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Pharmaceutical Research Network:

Estimated Enrollment: 36
Study Start Date: May 2005
Study Completion Date: October 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension
  • untreated intraocular pressure should be between 24-36 mm Hg inclusive
  • visual acuity should be 5/50 or better in both eyes

Exclusion Criteria:

  • presence of exfoliation syndrome or exfoliation glaucoma
  • contraindications to study medications
  • any anticipated change in systemic hypotensive therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00304785


Locations
Poland
Gabinety Okulistyczne
Bydgoszcz, Poland, PL-85-670
Kierownik Kliniki Okulistycznej Akademii Medycznej
Poznan', Poland, PL-61-848
Instytut Jaskry
Warsaw, Poland, 00415
Katdra Klinika Okulityki Akademii Medycznej w Warszawie
Warsaw, Poland, 02-005
Ordynator Oddziału Okulistycznego Międzyleski Szpital Specjalistyczny
Warszawa, Poland, PL-04-749
Sponsors and Collaborators
Pharmaceutical Research Network
Investigators
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Józef Kałużny, Professor Gabinety Okulistyczne
Principal Investigator: Krystyna Pecold, Professor Kierownik Kliniki Okulistycznej Akademii Medycznej
Principal Investigator: Roman Sobecki, Dr. n.med. Ordynator Oddziału Okulistycznego Międzyleski Szpital Specjalistyczny
Principal Investigator: Krystyna Czechowisz-Janicka, Professor Instytut Jaskry
Principal Investigator: Dariusz Kecik, Professor Katdra Klinika Okulityki Akademii Medycznej w Warszawie
  More Information

ClinicalTrials.gov Identifier: NCT00304785     History of Changes
Other Study ID Numbers: PRN 03-026
First Submitted: March 17, 2006
First Posted: March 20, 2006
Last Update Posted: October 24, 2007
Last Verified: October 2007

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Glaucoma
Eye Diseases
Latanoprost
Antihypertensive Agents